

REMARKS

The foregoing amendments are presented to place the application in compliance with the sequence rules under 37 CFR 1.821-1.825.

Applicants have submitted a revised Sequence Listing in both paper and computer readable form as required by 37 C.F.R. 1.821(c) and (e). Amendments directing its entry into the specification have also been incorporated herein. The content of the paper and computer readable copies are the same and no new matter has been added.

In view of the foregoing, it is believed that each requirement set forth in the Notice has been satisfied, and that the application is now in compliance with the sequence rules under 37 CFR 1.821-1.825. Accordingly, favorable examination on the merits is respectfully requested.

Respectfully submitted,

Kunihiko IIZUKA et al.

By: Warren Cheek
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/gtg
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
July 18, 2002

SEQUENCE LISTING

<110> IIZUKA, Kunihiko
DOBASHI, Kunio
UEHATA, Masayoshi

<120> Agent for the prophylaxis and treatment of interstitial pneumonia and fibroid lung

<130> 2001-1460A/WMC/00279

<140> 09/937,221
<141> 2002-07-18

<150> JP 11-122960
<151> 1999-04-28

<160> 2

<210> 1
<211> 19
<212> DNA
<213> Artificial Sequence

<220>

<223> Oligonucleotide designed to act as forward sequencing primer.

<400> 1
catggtgcat tgcgacaca

19

<210> 2
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<223> Oligonucleotide designed to act as reverse sequencing primer.

<400> 2
tcgccccatag taacatcacc t

21